Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Quark Pharmaceuticals

    • Most Recent Events

    • 03 Sep 2021 Results assessing safety and short term efficacy of teprasiran in preventing AKI in high-risk patients undergoing cardiac surgery published in the Circulation
    • 22 Oct 2018 According to a Quark Pharmaceuticals media release,data from this study will be presented at ASN 2018 and AAO 2018 Annual Meetings.
    • 07 Nov 2017 According to a Quark Pharmaceuticals media release, data will be presented at the EuroTIDES conference 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top